Virax Biolabs Group Limited (VRAX) Max Pain Analysis
Max pain is the strike price where aggregate option buyer payout is minimized at expiration. It represents the price at which option writers retain the most premium.
Virax Biolabs Group Limited (VRAX) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $1.2M, listed on NASDAQ, employing roughly 17 people, carrying a beta of 1.05 to the broader market. Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. Led by James Foster, public since 2022-07-21.
Max pain analysis shows the strike price where the most options expire worthless. No recent options activity for VRAX as of 2026-06-02; this typically reflects low options liquidity, a recently listed name, or a temporary data feed delay. Snapshot will refresh on the next active session.